ARCHIMED and La Caisse Acquire Stago for €550M in Revenue
Event summary
- ARCHIMED Diagnostics and minority investor La Caisse acquired Stago, a global leader in blood coagulation analysis, for an unspecified mix of equity and unitranche debt.
- Stago posted revenues of €550 million in 2025 and operates in 115 countries.
- Stago's leadership team is taking a minority stake as part of the deal, with Philippe Barroux, a 38-year Stago veteran, becoming the new CEO.
- ARCHIMED's MED Platform II fund, which closed on €3.5 billion in June 2023, is now 70% invested after this transaction.
The big picture
This acquisition underscores ARCHIMED's focus on the diagnostics sector, leveraging its MedValue template to drive growth through internationalization, innovation, and product range expansion. La Caisse's involvement highlights the strategic value of Stago's strong fundamentals and mission-critical role in medical diagnostics. With €9 billion in assets under management, ARCHIMED continues to prioritize healthcare investments, particularly in diagnostics, as part of its broader impact investing strategy.
What we're watching
- Execution Risk
- Whether ARCHIMED can deliver on its promise to accelerate Stago's growth through internationalization and innovation.
- Market Expansion
- The pace at which Stago can expand its sales and profits in both developed and developing nations.
- Innovation Pipeline
- How ARCHIMED's diagnostics expertise will impact the rollout of Stago's new generation of products.
Related topics